COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy.

MLA

Bondrescu, Mariana, et al. “COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy.” Biomolecules, vol. 14, no. 7, June 2024. EBSCOhost, https://doi.org/10.3390/biom14070777.

APA

Bondrescu, M., Dehelean, L., Farcas, S. S., Papava, I., Nicoras, V., Mager, D. V., Grecescu, A. E., Podaru, P. A., & Andreescu, N. I. (2024). COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy. Biomolecules, 14(7). https://doi.org/10.3390/biom14070777

Chicago

Bondrescu, Mariana, Liana Dehelean, Simona Sorina Farcas, Ion Papava, Vlad Nicoras, Dana Violeta Mager, Anca Eliza Grecescu, Petre Adrian Podaru, and Nicoleta Ioana Andreescu. 2024. “COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy.” Biomolecules 14 (7). doi:10.3390/biom14070777.